

# Report Package: Hot targets for empowered antibody and cell therapy technologies

<https://marketpublishers.com/r/R7CCE445BF2EN.html>

Date: December 2016

Pages: 202

Price: US\$ 2,090.00 (Single User License)

ID: R7CCE445BF2EN

## Abstracts

Report Package: Hot targets for empowered antibody and cell therapy technologies

This package contains three reports analyzing

BCMA,

CD123 and

CD22

as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

Fc-Engineered Antibodies;

Radioimmunotherapy;

Immunotoxins;

Antibody-Drug Conjugates;

T-Cell Redirecting Bispecific Antibodies;

Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss

Target background, scientific rationale & expression profiles;

Preclinical proof-of-concept;

Clinical experience;

Competitive landscape;

Drug or cell therapy profiles;

Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

[B-Cell Maturation Antigen \(BCMA\): hot target for emerging treatment modalities](#)

[CD123: a paradigmatic target for immunotherapeutic treatment modalities](#)

[CD22: a suitable antigen for targeted payload delivery by immunotherapeutics](#)

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.

## Contents

### REPORT 1:

#### **B-CELL MATURATION ANTIGEN (BCMA): HOT TARGET FOR EMERGING TREATMENT MODALITIES**

Target Background  
Target Antigen Expression Profile  
Preclinical Proof-of-Concept  
Clinical Indications & Treatment Options  
Clinical Experience with BCMA-Targeted Treatment Modalities  
Treatment Modalities & Competitive Landscape  
    Drug & Cell Therapy Candidate Profiles  
    CAR T-Cells  
    Antibody-Drug Conjugate (ADC)  
    T-Cell Redirecting Antibodies  
Company Profiles  
References

### REPORT 2:

#### **CD123: A PARADIGMATIC TARGET FOR IMMUNOTHERAPEUTIC TREATMENT MODALITIES**

Target Background & Scientific Rationale  
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics  
Clinical Experience with CD123-Targeted Treatment Modalities  
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics  
Competitive Landscape  
Profiles of Anti-CD123 Immunotherapeutics:  
    Immunotoxins  
    Naked Antibody  
    Fc-Engineered Antibodies  
    Antibody-Drug Conjugates  
    T-Cell Redirecting Bispecific Antibodies  
    Anti-CD123 CAR T-Cells  
Company Profiles  
References

ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

**REPORT 3:**

**CD22: A SUITABLE ANTIGEN FOR TARGETED PAYLOAD DELIVERY BY IMMUNOTHERAPEUTICS**

Target Background & Scientific Rationale

Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics

Competitive Landscape

Profiles of Anti-CD22 Immunotherapeutics

Naked antibodies;

Radioimmunotherapy (RIT);

Immunotoxins (IT);

Antibody-Dug Conjugates (ADC); and

Chimeric Antigen Receptor (CAR) T-Cells.

Profiles of Companies with CD22-Targeted Immunotherapeutics

References

ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics

## I would like to order

Product name: Report Package: Hot targets for empowered antibody and cell therapy technologies

Product link: <https://marketpublishers.com/r/R7CCE445BF2EN.html>

Price: US\$ 2,090.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R7CCE445BF2EN.html>